**Levels of Evidence for Adult and Pediatric Cancer Treatment Studies**

* **A1 Evidence.** Randomized controlled clinical trial (RCT) (double-blinded or nonblinded) with an end point of overall survival (OS) from a defined time, total mortality, or cause-specific mortality.
* **A2 Evidence.** Meta-analysis of RCTs with an end point of OS from a defined time, total mortality, or cause-specific mortality.
* **A3 Evidence.** RCT (double-blinded or nonblinded) with an end point of quality of life that is well-collected, clinically meaningful, and carefully assessed.
* **B1 Evidence.** RCT (double-blinded or nonblinded) with an end point of event-free survival (EFS), relapse-free survival (RFS), disease-free survival (DFS), or progression-free survival (PFS) differences.
* **B2 Evidence.** Meta-analysis of RCTs with an end point of EFS, DFS, PFS, or carefully assessed quality of life.
* **B3 Evidence.** RCT (double-blinded or nonblinded) with an end point of tumor response rate or quality-of-life measurement that does not reach the level described in A3.
* **B4 Evidence.** Nonrandomized, multicenter, prospective, controlled clinical trial with a planned comparison of efficacy including an end point of OS from a defined time, total mortality, cause-specific mortality, carefully assessed quality of life, EFS, DFS, PFS, or tumor response differences.
* **C1 Evidence.** Case series or other observational study design, including trials with nonconsecutive cases, with an end point of OS from a defined time, total mortality, cause-specific mortality, or carefully assessed quality of life.
* **C2 Evidence.** Case series or other observational study design, including trials with nonconsecutive cases, with an end point of EFS, RFS, DFS, or PFS differences.
* **C3 Evidence.** Case series or other observational study design, including trials with nonconsecutive cases, with an end point of tumor response rate or quality-of-life measurement that does not reach the level described in A3.
* **D Evidence.** Anecdotal experience or expert opinion.

**Last updated: 08/03/2023**